Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018200713) COMPOSITIONS AND METHODS FOR TARGETED TUMOR IMMUNOTHERAPY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/200713 International Application No.: PCT/US2018/029424
Publication Date: 01.11.2018 International Filing Date: 25.04.2018
IPC:
A61K 41/00 (2006.01) ,C07C 13/58 (2006.01) ,C07D 493/10 (2006.01) ,G01N 33/533 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
41
Medicinal preparations obtained by treating materials with wave energy or particle radiation
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
13
Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
28
Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof
32
with condensed rings
54
with three condensed rings
573
with three six-membered rings
58
Completely or partially hydrogenated anthracenes
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
493
Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
02
in which the condensed system contains two hetero rings
10
Spiro-condensed systems
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
531
Production of immunochemical test materials
532
Production of labelled immunochemicals
533
with fluorescent label
Applicants:
DANA-FARBER CANCER INSTITUTE, INC. [US/US]; 450 Brookline Avenue Office of General Counsel 10BP-372A Boston, Massachusetts 02215, US
Inventors:
NOVINA, Carl; US
DISTEL, Robert J.; US
NEIER, Steven; US
NOBILI, Alberto; US
Agent:
CLARKE, Daniel W.; US
CHACLAS, George N.; US
CHOW, Stephen Y.; US
COHEN, Jerry; US
COWLES, Christopher R.; US
EMMONS, Richard B.; US
FOLEY, Shawn P.; US
GOLDMAN, Gabriel; US
GOMES, David W.; US
HASAN, Shahid; US
JOBSE, Bruce D.; US
LOPEZ, Orlando; US
MARAIA, Joseph M.; US
MCGRATH, Daniel; US
MILLS, Steven M.; US
MOORE, Ronda P.; US
QUINN, Joseph P.; US
SCHEPPER, Marlo M.; US
SERIO, John C.; US
SORKIN, Paul D.; US
SUSAN, Janine M.; US
Priority Data:
62/489,91325.04.2017US
Title (EN) COMPOSITIONS AND METHODS FOR TARGETED TUMOR IMMUNOTHERAPY
(FR) COMPOSITIONS ET MÉTHODES DESTINÉES À UNE IMMUNOTHÉRAPIE ANTITUMORALE CIBLÉE
Abstract:
(EN) The present invention provides universal immunotherapy compositions useful for targeted treatment of cancers. The present invention utilizes in its various aspects, bifunctional compounds or complexes that contain at least two domains. One domain, referred to herein as a targeting moiety, binds an antigen on the surface of a tumor cell. The other domain, referred to herein as a pro-antigen, is designed to be inert to normal (non-diseased) cells and tissues, and to become activated (or "unmasked" or "uncaged") only upon exposure to light of an appropriate wavelength.
(FR) La présente invention concerne des compositions d'immunothérapie universelles servant au traitement ciblé de cancers. La présente invention utilise, dans ses divers aspects, des composés bifonctionnels ou des complexes qui contiennent au moins deux domaines. Un domaine, appelé dans la description fraction de ciblage, se lie à un antigène sur la surface d'une cellule tumorale. L'autre domaine, appelé dans la description pro-antigène, est conçu de sorte à être inerte envers les cellules normales et les tissus normaux (non malades), et à devenir activé (ou "non masqué" ou "non bloqué") uniquement lors de l'exposition à une lumière d'une longueur d'onde appropriée.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)